These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11745908)

  • 1. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans.
    Hirota N; Ito K; Iwatsubo T; Green CE; Tyson CA; Shimada N; Suzuki H; Sugiyama Y
    Biopharm Drug Dispos; 2001 Mar; 22(2):53-71. PubMed ID: 11745908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
    Allqvist A; Miura J; Bertilsson L; Mirghani RA
    Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
    Bakken GV; Rudberg I; Christensen H; Molden E; Refsum H; Hermann M
    Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
    J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
    Galetin A; Brown C; Hallifax D; Ito K; Houston JB
    Drug Metab Dispos; 2004 Dec; 32(12):1411-20. PubMed ID: 15342470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes.
    Iwatsubo T; Suzuki H; Shimada N; Chiba K; Ishizaki T; Green CE; Tyson CA; Yokoi T; Kamataki T; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Aug; 282(2):909-19. PubMed ID: 9262358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms.
    Lee HK; Moon JK; Chang CH; Choi H; Park HW; Park BS; Lee HS; Hwang EC; Lee YD; Liu KH; Kim JH
    Drug Metab Dispos; 2006 Jul; 34(7):1090-5. PubMed ID: 16581944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
    Gibbs MA; Thummel KE; Shen DD; Kunze KL
    Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
    Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
    Naritomi Y; Terashita S; Kagayama A
    Xenobiotica; 2004 May; 34(5):415-27. PubMed ID: 15370958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
    Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
    Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
    Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
    Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
    Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
    Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
    Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
    Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
    Klees TM; Sheffels P; Thummel KE; Kharasch ED
    Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
    Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
    Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.